Latest post

Pravin Dugel, M.D.: “Biological signal for efficacy of THR-149”

“As an investigator of THR-149, I was encouraged to see the results from its clinical phase 1 trial", Pravin Dugel, M.D., says.

back of the eye diseases, science community,

Phase 1 trial showed THR-149 is a highly potent plasma kallikrein inhibitor to treat DME

In 2019, Oxurion announced positive topline data for the compound THR-149, a highly potent plasma kallikrein inhibitor to treat diabetic macular edema (DME).

back of the eye diseases, science community,

Arshad Khanani: “Initial data of phase 1 trial of THR-687 point to clinical efficacy”

Arshad Khanani, M.D., M.A. about the clinical phase 1 data of THR-687.

back of the eye diseases, science community,

Positive phase 1 data indicate THR-687 could be an effective therapy for patients with DME

Oxurion kick-started 2020 with positive topline data from phase 1 clinical trial evaluating THR-687 for treatment of DME.

science community

A strategic focus for Oxurion: researching and developing non-VEGF pathways

Jean Feyen, PhD., Chief Scientific Officer, and Andy De Deene, M.D., Global Head of Development, explain why Oxurion decided to focus on non-VEGF pathways.

back of the eye diseases, eye community,

Oxurion NV Partners with Prevent Blindness to Educate Public on Diabetes-related Eye Disease

Both Oxurion and Prevent Blindness join forces during November to educate the public on risk factors, symptoms, treatment options, and financial assistance resources.

back of the eye diseases, eye community,

3 reasons why we need to raise diabetic eye disease awareness

Diabetic eye diseases affect millions of people globally, and still there's a high unmet need in diagnosis and treatment. It's high time to get the message across to risk groups.

back of the eye diseases, eye community,

Creating Diabetic Eye Disease Awareness with Prevent Blindness

This November, in support of Diabetic Eye Disease Awareness Month, Oxurion is partnering with Prevent Blindness and its sight saving efforts.

science community

“An aspiring name to reflect our focus and ambition”

“The new name comes from combining the words Oxygen and Orion”, explains CEO Patrik De Haes, MD. “Raising oxygen levels in cells plays a key role in helping prevent and reverse ...

back of the eye diseases, science community,

Alan Stitt: “We need therapies fighting different hallmarks simultaneously”

PDR and DME are two manifestations of diabetic retinopathy (DR), and in many respects they stem from the same cause, explains professor Alan Stitt.

eye community

Rajat Agrawal: “Join forces to fight eye disease in developing countries”

“In those parts of the world there are many patients who lack access to routine retinal care,” Dr. Agrawal explains. “We aim to provide clinical care by sending retina ...

eye community

“Oxurion remains innovator in novel retinal therapies”

“There is currently an explosion in R&D activities in the retinal space. Numerous potential new therapies are ready for translation into clinical studies, making this a truly ...